Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Understanding the Enemy: The Immunology of RA To conquer RA, we must first map its treacherous terrain
SGLT2 inhibitors In people with type 2 diabetes, cardiovascular outcome trials (CVOTs) with empagliflozin, canagliflozin and dapagliflozin have established that use of these SGLT2 inhibitors reduces the risk of CV events (quantified as a composite of non-fatal myocardial infarction, non-fatal stroke and CV death) versus placebo in: Established atherosclerotic CV disease (ASCVD
Rubino DM, Greenway FL, Khalid U et al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial
et al (2015) Oncol Lett.
Introduction Diabetes has been one of the fastest growing public health issues worldwide in recent decades
US$ 20.18
US$ 20.04
US$ 24.16
US$ 23.06
US$ 21.18
